ArticleCNS drugs2022
The Potential of KCNQ Potassium Channel Openers as Novel Antidepressants.
Article in CNS drugs, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed.
- Effects of the KCNQ (Kv7) Channel Opener Ezogabine on Resting-State Functional Connectivity of Striatal Brain Reward Regions, Depression, and Anhedonia in Major Depressive Disorder: Results From a Randomized Controlled Trial.Biological psychiatry · 2025Trial
- Effects of KCNQ potassium channel modulation on ventral tegmental area activity and connectivity in individuals with depression and anhedonia.Molecular psychiatry · 2025Trial
- The effect of M-current activation on controller gain and obstructive sleep apnoea severity: a randomised controlled trial using flupirtine.The Journal of physiology · 2025Trial
- Azetukalner, a Novel KV7 Potassium Channel Opener, in Adults With Major Depressive Disorder: A Randomized Clinical Trial.JAMA network open · 2025Trial
- Next-Generation Pharmacotherapies for Unipolar Mood Disorders: A Leading Article on Phase II/III Drug Development Across Diverse Mechanisms.CNS drugs · 2026Review
- Towards precision psychiatry: initial foundations and future directions.Nature reviews. Drug discovery · 2026Review
- Evidence for Potentiation of M-Type Potassium Current by Flavonoid Corylin (3-(2,2-Dimethylchromen-6-yl)-7-hydroxychromen-4-one).Pharmaceuticals (Basel, Switzerland) · 2026Article
- Construction of a depression risk prediction model for hepatitis B patients based on machine learning strategy.PloS one · 2026Article
- Anhedonia in Depressive Disorder and Schizophrenia: An Overview of Causes, Diagnosis, and Treatment.Medical science monitor : international medical journal of experimental and clinical research · 2025Review
- VTA network dominance in depression confers distinct psychopathological states through blunted neural tracking of reward prediction errors.Research square · 2025Article
- A novel medication approach to treating obstructive sleep apnoea.The Journal of physiology · 2025Article
- Cross-species dissection of the modular role of the ventral tegmental area in depressive disorders.Neuroscience · 2025Review
- Sex-specific gene expression and weighted co-expression network analysis suggest distinct sex-specific molecular signatures in acutely suicidal MDD-patients without somatic comorbidities.Frontiers in genetics · 2025Article
- New and emerging pharmacologic treatments for MDD.Frontiers in psychiatry · 2025Review
- Potassium channels in depression: emerging roles and potential targets.Cell & bioscience · 2024Review
- Novel therapeutic targets for major depressive disorder related to oxidative stress identified by integrative multi-omics and multi-trait study.Translational psychiatry · 2024Article
- The involvement of KTranslational psychiatry · 2024Review
- Article
- Midbrain glutamatergic circuit mechanism of resilience to socially transferred allodynia in male mice.Nature communications · 2024Article
- New and emerging approaches to treat psychiatric disorders.Nature medicine · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Major depressive disorder (MDD) is a leading cause of disability worldwide and less than one-third of patients with MDD achieve stable remission of symptoms, despite currently available treatments. Although MDD represents a serious health problem, a complete understanding of the neurobiological mechanisms underlying this condition continues to be elusive. Accumulating evidence from preclinical and animal studies provides support for the antidepressant potential of modulators of KCNQ voltage-gated potassium (K
Indexed as
Identifiers
35258812What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.